Gene expression profiling has indicated that the up-regulation of specific subsets of chemokines/cytokine/ growth factors is often linked to poorer prognosis for women with invasive mammary carcinoma. Chemokines are important for the recruitment of leukocytes to the tumor microenvironment (TME) which can affect invasion and metastasis. It has been proposed that specific chemokines released by circulating tumor cells signal to leukocytes in the pre-metastatic niche and entrain myeloid cells to exhibit an anti-tumorigenic phenotype. The entrainment process is thought to require activation of neutrophil NADPH oxidase to ultimately generate extracellular H2O2, which is toxic to tumor cells. This process is reported to be dependent upon activation of PI3 kinase. The goal of this research is evaluate mechanisms of entrainment and to characterize the role of inhibition of PI3 kinase in chemokine mediated entrainment of leukocytes. We hypothesize that perisurgical delivery of entraining chemokines to cancer patients may reduce recurrence and metastasis. Moreover, current PI3K inhibitor therapies for breast cancer patients might fail if they reverse this entrainment, counteract the effect of anti-tumor leukocytes, and thus promote metastasis. There are three specific aims for this study: 1) Using an immunocompetent mouse model we will determine whether manipulation of CCL2, CCL5, CXCL1, CXCL12 and/or TGF-beta levels will differentially effect the recruitment of anti- or pro-tumor leukocytes into the primary tumor and the pre-metastatic niche.
Aim1 B. We will determine whether blocking the receptors for each of these chemokines will facilitate or disrupt the metastatic capacity of mammary carcinoma;2) Using immunocompetent mice, intravital imaging, and ex-vivo micro-bioreactors we will determine whether current therapeutics for breast cancer that inhibit PI3K are able to block or facilitate chemokine-mediated 'entrainment"""""""" of myeloid cells in tumor bearing mice;We will deliver PI3K inhibitors to tumor bearing mice, isolate myeloid cells, and determine whether neutrophils respond to entraining chemokines with induction of H2O2 and have the capacity to kill tumor cells;3) We will evaluate changes in the myeloid 'entrainment'status of cancer patients before and after chemotherapy and determine whether leukocytes can be entrained 'ex vivo'. Using a humanized mouse model and implanted patient tumors, we will determine whether drug induced alterations in myeloid entrainment that result in reduced tumor cell killing and/or enhanced metastasis correlates with time to progression in the patient. In humanized mice, we will also compare the effects of ex vivo treatment with chemokines or PI3K inhibitors on 'entrainment'properties of circulating myeloid cells of cancer patients prior to surgery, after surgery, or perisurgery to determine the appropriate time to deliver entraining chemokines or PI3K inhibitors.

Public Health Relevance

Using novel methodologies, we will define the chemokine mediated signals that are needed to entrain leukocytes to kill tumor cells in the pre-metastatic niche and inhibit establishment of metastatic breast cancer lesions. Results will reveal strategies to most effectively teach the immune system to better protect tissues from cancer metastasis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Anatomy/Cell Biology
Schools of Medicine
United States
Zip Code
Sai, Jiqing; Rogers, Matthew; Hockemeyer, Kathryn et al. (2016) Study of Chemotaxis and Cell-Cell Interactions in Cancer with Microfluidic Devices. Methods Enzymol 570:19-45
Richmond, Ann; Yang, Jinming (2016) The role of NF-kB in modulating antitumor immunity. Oncoimmunology 5:e1005522
Johnson, Douglas B; Estrada, Monica V; Salgado, Roberto et al. (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582
Vilgelm, Anna E; Johnson, C Andrew; Prasad, Nripesh et al. (2016) Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. J Natl Cancer Inst 108:djv406
Duvall-Noelle, N; Karwandyar, A; Richmond, A et al. (2016) LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex. Oncogene 35:1122-33
Vilgelm, Anna; Richmond, Ann (2015) Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses. Oncoimmunology 4:e1009299
Su, Yingjun; Richmond, Ann (2015) Chemokine Regulation of Neutrophil Infiltration of Skin Wounds. Adv Wound Care (New Rochelle) 4:631-640
Liu, Yan; Hawkins, Oriana E; Vilgelm, Anna E et al. (2015) Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clin Cancer Res 21:5338-48
Vilgelm, Anna E; Pawlikowski, Jeff S; Liu, Yan et al. (2015) Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75:181-93
Singh, Vandana; Raghuwanshi, Sandeep K; Smith, Nikia et al. (2014) G Protein-coupled receptor kinase-6 interacts with activator of G protein signaling-3 to regulate CXCR2-mediated cellular functions. J Immunol 192:2186-94

Showing the most recent 10 out of 63 publications